# Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants

> **NCT06737042** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Gan and Lee Pharmaceuticals, USA** · enrollment: 285 (estimated)

## Conditions studied

- Obesity and Overweight

## Interventions

- **DRUG:** GZR18
- **DRUG:** Tirzepatide

## Key facts

- **NCT ID:** NCT06737042
- **Lead sponsor:** Gan and Lee Pharmaceuticals, USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-02-12
- **Primary completion:** 2026-02-09
- **Final completion:** 2026-06-22
- **Target enrollment:** 285 (ESTIMATED)
- **Last updated:** 2025-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06737042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06737042, "Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT06737042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*